Displaying 1661 - 1680 of 4375
FTC Approves Final Order with Sherwin-Williams and Valspar, Preserving Competition in the North American Market for Industrial Wood Coatings
Sherwin-Williams/Valspar, In the Matter of
The Sherwin-Williams Company agreed to settle charges that its proposed $11.3 billion acquisition of Valspar Corporation is likely anticompetitive by selling Valspar’s North America Industrial Wood Coatings Business to Axalta Coating Systems Ltd. The transaction would combine Sherwin-Williams and Valspar, two of the top three industrial wood coatings manufacturers. According to the complaint, the acquisition as originally proposed likely would reduce competition in the North American market for industrial wood coatings used to make furniture, kitchen cabinets, and building products. Under the terms of the consent agreement, Sherwin-Williams will divest to Axalta two Valspar industrial wood coatings plants, one in High Point, North Carolina, and the other in Cornwall, Ontario. Axalta will also receive the research and development facilities, warehouses and testing facilities of Valspar’s Industrial Wood Coatings Business, as well as customer contracts, intellectual property, inventory, accounts receivable, government licenses and permits, and business records.
1707005 Informal Interpretation
Prepared Statement of the Federal Trade Commission on "Antitrust Concerns and the FDA Approval Process,” Before the Subcommittee on Regulatory Reform, Commercial and Antitrust Law of the Judiciary Committee, United States House of Representatives
FTC Testifies before House Judiciary Committee’s Subcommittee on Regulatory Reform, Commercial and Antitrust Law about Antitrust Concerns and the FDA Approval Process
Streamlining Licensing Across State Lines: Initiatives to Enhance Occupational License Portability
1707004 Informal Interpretation
FTC to Hold First Roundtable on Economic Liberty
Death By A Thousand Haircuts: Economic Liberty and Occupational Licensure Reform
FTC Six-Month Accomplishments
Doctors Hospital at Renaissance/Mission Regional Medical Center
1707003 Informal Interpretation
1707002 Informal Interpretation
FTC Requires Baxter International and Claris Lifesciences to Divest 2 Types of Pharmaceutical Products as Condition of Baxter Acquiring Injectable Drugs Business from Claris
FTC Acting Chairman Ohlhausen Selects D. Bruce Hoffman as Acting Director of the Agency’s Bureau of Competition
FTC Staff Provides Additional Comment and Testimony in Tennessee Opposing Mountain States’ and Wellmont’s Certificate of Public Advantage Application
Tennessee Department of Health, Certificate of Public Advantage Hearing Testimony
Acting FTC Chairman Ohlhausen Appoints Neil Chilson as Acting Chief Technologist
Displaying 1661 - 1680 of 4375